Shares of Seattle Genetics rose $1.55, or 3.3%, in after-hours trading on Aug. 17 after the firm won a third US indication for its CD30-directed antibody-drug conjugate Adcetris (brentuximab vedotin) from an accelerated to a regular approval – classical Hodgkin lymphoma (HL) in patients at high risk of relapse or progression as post-autologous hematopoietic stem-cell transplantation (auto-HSCT) consolidation.
Shares of Seattle Genetics rose $1.55, or 3.3%, in after-hours trading on Aug. 17 after the firm won a third US indication for its CD30-directed antibody-drug conjugate Adcetris (brentuximab vedotin) from an accelerated to a regular approval – classical Hodgkin lymphoma (HL) in patients at high risk of relapse or progression as post-autologous hematopoietic stem-cell transplantation (auto-HSCT) consolidation.
The approval was based on data from Seattle Genetics' Phase III AETHERA study.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
